This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01131/identifier/chemspider/
n22http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB01131/identifier/chebi/
n9http://www.drugs.com/cons/
admshttp://www.w3.org/ns/adms#
n7http://linked.opendata.cz/resource/drugbank/drug/DB01131/identifier/wikipedia/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01131/identifier/pharmgkb/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/drug/DB01131/identifier/kegg-compound/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01131/identifier/pubchem-compound/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n4http://linked.opendata.cz/resource/drugbank/drug/DB01131/identifier/pubchem-substance/
n15http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01131/identifier/drugbank/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01131
rdf:type
n5:Drug
n5:description
Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, Plasmodium falciparum and Plasmodium vivax, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite.
n5:group
approved
n5:halfLife
Approximately 20 hours
n5:indication
For the causal prevention and suppression of malaria caused by susceptible strains of <i>P. falciparum</i> and other species of Plasmodium found in some geographical areas of the world.
owl:sameAs
n11:DB01131 n22:DB01131
dcterms:title
Proguanil
adms:identifier
n4:46506228 n7:Proguanil n16:4754 n17:DB01131 n18:8455 n19:PA451124 n20:6178111 n21:C07631
n5:mechanismOfAction
Proguanil inhibits the dihydrofolate reductase of plasmodia and thereby blocks the biosynthesis of purines and pyrimidines, which are essential for DNA synthesis and cell multiplication. This leads to failure of nuclear division at the time of schizont formation in erythrocytes and liver.
n5:packager
n13:271B45D7-363D-11E5-9242-09173F13E4C5 n13:271B45D5-363D-11E5-9242-09173F13E4C5 n13:271B45D6-363D-11E5-9242-09173F13E4C5
n5:synonym
Proguanilum Chloroguanide Chlorguanide N-(4-Chlorophenyl)-n'-(isopropyl)-imidodicarbonimidic diamide 1-(P-Chlorophenyl)-5-isopropylbiguanide N-(4-Chlorophenyl)-n'-(isopropyl)-imidodicarbonimidic diamide
n5:foodInteraction
Take with food.
n5:proteinBinding
Approximately 75%
n5:synthesisReference
Dhananjay Govind Sathe, Harish Kashinath Mondkar, Tanaji Shamrao Jadhav, Nitin Nivrutti Hagavane, "Process of Preparation of Proguanil." U.S. Patent US20110263901, issued October 27, 2011.
foaf:page
n9:proguanil.html
n5:IUPAC-Name
n6:271B45DC-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B45E2-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B45E1-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B45DE-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B45DF-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B45E0-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B45F2-363D-11E5-9242-09173F13E4C5 n6:271B45DA-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B45F4-363D-11E5-9242-09173F13E4C5 n6:271B45D8-363D-11E5-9242-09173F13E4C5 n6:271B45DB-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B45D9-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n15:P01BB01
n5:H-Bond-Acceptor-Count
n6:271B45E8-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B45E9-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B45E3-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B45E4-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B45E6-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B45E5-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B45E7-363D-11E5-9242-09173F13E4C5
n5:absorption
Rapidly and well absorbed in humans following oral doses ranging from 50 to 500 mg.
n5:affectedOrganism
Plasmodium
n5:casRegistryNumber
500-92-5
n5:Bioavailability
n6:271B45EE-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B45F0-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B45F1-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B45F3-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B45ED-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B45EC-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B45EF-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B45DD-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B45EA-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B45EB-363D-11E5-9242-09173F13E4C5